Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aminolevulinic acid (Primary)
  • Indications Actinic keratosis; Skin cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 11 Feb 2016 Results from this trial will be presented at the 14th Annual South Beach Symposium, according to a Biofrontera media release.
    • 27 Jan 2011 Biofrontera has received a positive interim report of the responsible committee of the European Medicines Agency, according to a company media release.
    • 16 Dec 2010 According to a Biofrontera media release, EMEA has sent official summaries and preliminary questions of the reviewers about the approval dossier, and subject to satisfactory answers to the questions raised, the review will recommended the drug approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top